Market Research

Liposome Drug Delivery Market (Liposome Structure: Unilamellar Liposomes, Multilamellar Liposomes, and Others; Product: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and Others) - Global Industry Analysis, Size, Share, Growth, Tre

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 180 Pages Transparency Market Research Pvt. Ltd. August, 2023 TNPR18249886
Best Price Guarantee
Price from $5,795
Length 180 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date August, 2023
SKU TNPR18249886

Liposome Drug Delivery Market (Liposome Structure: Unilamellar Liposomes, Multilamellar Liposomes, and Others; Product: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Liposome Drug Delivery Market – Scope of Report

TMR’s report on the global liposome drug delivery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global liposome drug delivery market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global liposome drug delivery market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the liposome drug delivery market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global liposome drug delivery market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global liposome drug delivery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global liposome drug delivery market.

The report delves into the competitive landscape of the global liposome drug delivery market. Key players operating in the global liposome drug delivery market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global liposome drug delivery market profiled in this report.

Key Questions Answered in Global Liposome Drug Delivery Market Report
  • What is the sales/revenue generated by liposome drug delivery across all regions during the forecast period?
  • What are the opportunities in the global liposome drug delivery market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Liposome Drug Delivery Market – Research Objectives and Research Approach

The comprehensive report on the global liposome drug delivery market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global liposome drug delivery market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global liposome drug delivery market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Liposome Drug Delivery Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Liposome Drug Delivery Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Overview: Liposome Drug delivery Systems
5.3. Regulatory Scenario
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Liposome Drug Delivery Market Analysis and Forecast, by Liposome Structure
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Liposome Structure, 2017-2031
6.3.1. Unilamellar Liposomes
6.3.1.1. Small
6.3.1.2. Large
6.3.2. Multilamellar liposomes
6.3.3. Others
6.4. Market Attractiveness Analysis, by Liposome Structure
7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product, 2017-2031
7.3.1. Liposomal Doxorubicin
7.3.2. Liposomal Paclitaxel
7.3.3. Liposomal Amphotericin B
7.3.4. Others
7.4. Market Attractiveness Analysis, by Product
8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Technology, 2017-2031
8.3.1. Stealth Liposome Technology
8.3.2. Non PEGylated Liposome Technology
8.3.3. DepoFoam Liposome Technology
8.3.4. Lysolipid Thermally Sensitive Liposome Technology
8.4. Market Attractiveness Analysis, by Technology
9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Application, 2017-2031
9.3.1. Fungal Diseases
9.3.2. Cancer Therapy
9.3.3. Pain Management
9.3.4. Viral Vaccines
9.3.5. Photodynamic Therapy
9.3.6. Others
9.4. Market Attractiveness Analysis, by Application
10. Global Liposome Drug Delivery Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017-2031
10.3.1. Hospitals
10.3.2. Specialty Centers
10.3.3. Ambulatory Surgical Centers
10.3.4. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global Liposome Drug Delivery Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Liposome Drug Delivery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Liposome Structure, 2017-2031
12.2.1. Unilamellar Liposomes
12.2.1.1. Small
12.2.1.2. Large
12.2.2. Multilamellar liposomes
12.2.3. Others
12.3. Market Value Forecast, by Product, 2017-2031
12.3.1. Liposomal Doxorubicin
12.3.2. Liposomal Paclitaxel
12.3.3. Liposomal Amphotericin B
12.3.4. Others
12.4. Market Value Forecast, by Technology, 2017-2031
12.4.1. Stealth Liposome Technology
12.4.2. Non PEGylated Liposome Technology
12.4.3. DepoFoam Liposome Technology
12.4.4. Lysolipid Thermally Sensitive Liposome Technology
12.5. Market Value Forecast, by Application, 2017-2031
12.5.1. Fungal Diseases
12.5.2. Cancer Therapy
12.5.3. Pain Management
12.5.4. Viral Vaccines
12.5.5. Photodynamic Therapy
12.5.6. Others
12.6. Market Value Forecast, by End-user, 2017-2031
12.6.1. Hospitals
12.6.2. Specialty Centers
12.6.3. Ambulatory Surgical Centers
12.6.4. Others
12.7. Market Value Forecast, by Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Liposome Structure
12.8.2. By Product
12.8.3. By Technology
12.8.4. By Application
12.8.5. By End-user
12.8.6. By Country
13. Europe Liposome Drug Delivery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Liposome Structure, 2017-2031
13.2.1. Unilamellar Liposomes
13.2.1.1. Small
13.2.1.2. Large
13.2.2. Multilamellar liposomes
13.2.3. Others
13.3. Market Value Forecast, by Product, 2017-2031
13.3.1. Liposomal Doxorubicin
13.3.2. Liposomal Paclitaxel
13.3.3. Liposomal Amphotericin B
13.3.4. Others
13.4. Market Value Forecast, by Technology, 2017-2031
13.4.1. Stealth Liposome Technology
13.4.2. Non PEGylated Liposome Technology
13.4.3. DepoFoam Liposome Technology
13.4.4. Lysolipid Thermally Sensitive Liposome Technology
13.5. Market Value Forecast, by Application, 2017-2031
13.5.1. Fungal Diseases
13.5.2. Cancer Therapy
13.5.3. Pain Management
13.5.4. Viral Vaccines
13.5.5. Photodynamic Therapy
13.5.6. Others
13.6. Market Value Forecast, by End-user, 2017-2031
13.6.1. Hospitals
13.6.2. Specialty Centers
13.6.3. Ambulatory Surgical Centers
13.6.4. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
13.7.1. Germany
13.7.2. U.K
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Liposome Structure
13.8.2. By Product
13.8.3. By Technology
13.8.4. By Application
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Liposome Structure, 2017-2031
14.2.1. Unilamellar Liposomes
14.2.1.1. Small
14.2.1.2. Large
14.2.2. Multilamellar liposomes
14.2.3. Others
14.3. Market Value Forecast, by Product, 2017-2031
14.3.1. Liposomal Doxorubicin
14.3.2. Liposomal Paclitaxel
14.3.3. Liposomal Amphotericin B
14.3.4. Others
14.4. Market Value Forecast, by Technology, 2017-2031
14.4.1. Stealth Liposome Technology
14.4.2. Non PEGylated Liposome Technology
14.4.3. DepoFoam Liposome Technology
14.4.4. Lysolipid Thermally Sensitive Liposome Technology
14.5. Market Value Forecast, by Application, 2017-2031
14.5.1. Fungal Diseases
14.5.2. Cancer Therapy
14.5.3. Pain Management
14.5.4. Viral Vaccines
14.5.5. Photodynamic Therapy
14.5.6. Others
14.6. Market Value Forecast, by End-user, 2017-2031
14.6.1. Hospitals
14.6.2. Specialty Centers
14.6.3. Ambulatory Surgical Centers
14.6.4. Others
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Liposome Structure
14.8.2. By Product
14.8.3. By Technology
14.8.4. By Application
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Liposome Drug Delivery Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Liposome Structure, 2017-2031
15.2.1. Unilamellar Liposomes
15.2.1.1. Small
15.2.1.2. Large
15.2.2. Multilamellar liposomes
15.2.3. Others
15.3. Market Value Forecast, by Product, 2017-2031
15.3.1. Liposomal Doxorubicin
15.3.2. Liposomal Paclitaxel
15.3.3. Liposomal Amphotericin B
15.3.4. Others
15.4. Market Value Forecast, by Technology, 2017-2031
15.4.1. Stealth Liposome Technology
15.4.2. Non PEGylated Liposome Technology
15.4.3. DepoFoam Liposome Technology
15.4.4. Lysolipid Thermally Sensitive Liposome Technology
15.5. Market Value Forecast, by Application, 2017-2031
15.5.1. Fungal Diseases
15.5.2. Cancer Therapy
15.5.3. Pain Management
15.5.4. Viral Vaccines
15.5.5. Photodynamic Therapy
15.5.6. Others
15.6. Market Value Forecast, by End-user, 2017-2031
15.6.1. Hospitals
15.6.2. Specialty Centers
15.6.3. Ambulatory Surgical Centers
15.6.4. Others
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Liposome Structure
15.8.2. By Product
15.8.3. By Technology
15.8.4. By Application
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Liposome Structure, 2017-2031
16.2.1. Unilamellar Liposomes
16.2.1.1. Small
16.2.1.2. Large
16.2.2. Multilamellar liposomes
16.2.3. Others
16.3. Market Value Forecast, by Product, 2017-2031
16.3.1. Liposomal Doxorubicin
16.3.2. Liposomal Paclitaxel
16.3.3. Liposomal Amphotericin B
16.3.4. Others
16.4. Market Value Forecast, by Technology, 2017-2031
16.4.1. Stealth Liposome Technology
16.4.2. Non PEGylated Liposome Technology
16.4.3. DepoFoam Liposome Technology
16.4.4. Lysolipid Thermally Sensitive Liposome Technology
16.5. Market Value Forecast, by Application, 2017-2031
16.5.1. Fungal Diseases
16.5.2. Cancer Therapy
16.5.3. Pain Management
16.5.4. Viral Vaccines
16.5.5. Photodynamic Therapy
16.5.6. Others
16.6. Market Value Forecast, by End-user, 2017-2031
16.6.1. Hospitals
16.6.2. Specialty Centers
16.6.3. Ambulatory Surgical Centers
16.6.4. Others
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & South Africa
16.8. Market Attractiveness Analysis
16.8.1. By Liposome Structure
16.8.2. By Product
16.8.3. By Technology
16.8.4. By Application
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix, by tier and size of companies
17.2. Market Share Analysis, by Company, 2021
17.3. Company Profiles
17.3.1. Johnson & Johnson Services, Inc.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Gilead Sciences, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Sun Pharmaceutical Industries Ltd.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Novartis AG
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Teva Pharmaceutical Industries Ltd
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Janssen Pharmaceuticals, Inc.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. CELSION Corporation
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Abbott
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Ipsen Pharma
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Spectrum Pharmaceuticals, Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
17.3.11. Takeda Pharmaceutical Company Limited
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings